# US 10,864,258 B2 · Method for treating pancreatic cancer with Toxoplasma gondii vaccine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,864,258 B2
- Document ID: US10864258B2
- Status: Granted
- Kind: B2
- Application number: 14/787,488
- Filed: 2014-04-15
- Published: 2016-03-10
- Granted: 2020-12-15
- Earliest claimed: 2013-04-29
- Assignees: Trustees of Dartmouth College
- Applicants: Trustees of Dartmouth College
- Inventors: David J. Bzik; Barbara A. Fox; Kiah L. Sanders
- Web page: https://patentgrep.com/patent/US10864258B2

## CPC

- C12N 9/86: acting on amide bonds in cyclic amides, e.g. penicillinase {(3.5.2)}
- A61K 39/002: Protozoa antigens
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/42: Cancer antigens
- C12N 1/36: Adaptation or attenuation of cells
- C12N 9/001: {acting on the CH-CH group of donors (1.3)}
- C12N 9/1018: {Carboxy- and carbamoyl transferases (2.1.3)}
- C12N 9/1077: {Pentosyltransferases (2.4.2)}
- C12N 9/88: Lyases (4.)
- C12N 9/93: {Ligases (6)}
- A61K 2039/522: {avirulent or attenuated}
- A61K 2039/523: {expressing foreign proteins}
- A61K 2039/57: {characterised by the type of response, e.g. Th1, Th2}
- A61K 2039/585: {wherein the target is cancer}
- A61K 2039/852: {Pancreas}
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Attenuated Toxoplasma gondii mutants and methods using the same as vaccines in the prevention or treatment pancreatic cancer are provided.

## Claims

### Claim 1

A method for treating pancreatic cancer comprising administering at least six doses of an irradiated pancreatic tumor cell to a subject in need of treatment over a period of 36 days, wherein the irradiated tumor cell harbors an effective amount of an attenuated mutant of Toxoplasma gondii comprising a knockout mutation of orotidine 5′-monophosphate decarboxylase; a knockout mutation of uridine phosphorylase; and nucleic acids encoding one or more of annexin A2, plectin-1, fetoacinar pancreatic protein, or tubulin tyrosine ligase-like family member 4, thereby treating the subject's pancreatic cancer.

### Claim 2 (depends on 1)

The method of claim 1, wherein the attenuated mutant further comprises in its genome nucleic acid molecules encoding one or more exogenous proteins.